target discovery

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data using machine learning to translate human disease biology and advance precision medicines. Its Elion platform connects patient data from electronic medical records with experimental data captured in zebrafish models using proprietary computer vision to identify high-confidence drug targets. The company is advancing programs in cardiometabolic, neurological, and rare diseases, including familial dilated cardiomyopathy, atherosclerosis, and epilepsy.

computer visiondrug discoveryin vivo validationmachine learningphenomics

Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK. It develops accessible off-the-shelf cancer RNA immunotherapies and vaccines targeting shared, aberrantly expressed tumour-specific antigens (aeTSAs), known as Cryptigen TSAs, hidden in 'junk DNA'. Its proprietary CryptoMap platform identifies these targets across difficult-to-treat cancers.

Bioinformaticscomputational biologyimmunogenicity assaysRNA vaccine design

Etiome is a biotechnology company developing and deploying Biostaged Medicines, stage-specific therapies delivered to the right patient population at the right time. By building detailed models of molecular changes over the course of disease and applying single-cell omics and artificial intelligence, Etiome uncovers hidden patterns of disease progression to identify disease-modifying targets and biomarkers. Founded in 2021, originating from Flagship Pioneering's Preemptive Health and Medicine initiative.

Artificial Intelligencebiomarker discoverycomputational biologydrug discoverymachine learningsingle-cell omics

IMPECCURE is an early-stage biotech company developing precise and innovative therapeutics for activity-dependent neurological disorders, including drug-resistant epilepsy and related conditions. Its novel active neuron tagging system enables highly accurate target discovery and gene therapy development tailored to dysfunctional neural circuits, with a focus on first-in-class solutions.

active neuron tagging systemgene therapy development